Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 274-286

  Vagace, Jose Manuel ^a   de la Maya, Maria Dolores ^a   Caceres Marzal, Cristina ^a   Gonzalez de Murillo, Silvia ^b   Gervasini, Guillermo ^b  

^a Materno Infantil Hospital   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Central nervous system; Chemotherapy; Lymphoblastic leukemia lymphoma; Neurotoxicity; Pharmacogenetics

Indexed keywords

ANTICONVULSIVE AGENT; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ENALAPRIL; HYDROCORTISONE; IMATINIB; METHOTREXATE; NELARABINE; PREDNISONE; STEROID; VINCRISTINE; VORICONAZOLE;

ACUTE BRAIN DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ANOSMIA; APHASIA; ARACHNOIDITIS; ASEPTIC MENINGITIS; ATAXIA; BLINDNESS; BLOOD CLOTTING DISORDER; BLURRED VISION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CAUDA EQUINA SYNDROME; CEREBELLUM DISEASE; CEREBRAL SALT WASTING; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR ACCIDENT; CHRONIC LEUKOENCEPHALOPATHY; CONFUSION; CONSCIOUSNESS DISORDER; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; EYE BURNING; EYE DISEASE; FOCAL EPILEPSY; GENETIC POLYMORPHISM; HEAD MOVEMENT; HEADACHE; HEMIPARESIS; HETEROZYGOTE; HOMOZYGOTE; HORNER SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTRACRANIAL HYPERTENSION; LETHARGY; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LYMPHOBLASTOMA; MOTOR RETARDATION; MULTIPLE CYCLE TREATMENT; MYDRIASIS; NEUROIMAGING; NEUROTOXICITY; NYSTAGMUS; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOSARCOMA; PARTIAL THROMBOPLASTIN TIME; PHARMACOGENETICS; PLASMA TRANSFUSION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTHROMBIN TIME; PSEUDOBULBAR PALSY; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPINAL CORD DISEASE; SUBACUTE LEUKOENCEPHALOPATHY; THROMBOCYTE COUNT; THROMBOSIS; TONIC CLONIC SEIZURE; TRANSVERSE MYELOPATHY; VISUAL HALLUCINATION; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; NEUROTOXICITY SYNDROMES; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STROKE;

EID: 84867842532     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.04.003     Document Type: Review

References (111)

1. Cortelazzo S., Ponzoni M., Ferreri A.J., Hoelzer D. Lymphoblastic lymphoma. Critical Reviews in Oncology/Hematology 2011, 79:330-343.
2. Sandlund J.T., Link M.P. Malignant lymphomas in childhood. Hematology basic principles and practice 2009, 1303-1313. Elsevier. 5th ed. R. Hoffman, E.J. Benz, S.J. Shattil, B. Furie, L.E. Silberstein, P. McGlave (Eds.).
3. Laningham F.H., Kun L.E., Reddick W.E., Ogg R.J., Morris E.B., Pui C.H. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 2007, 49:873-888.
4. Reddick W.E., Laningham F.H., Glass J.O., Pui C.H. Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia. Neuroradiology 2007, 49:889-904.
5. Lo Nigro L., Di Cataldo A., Schiliro G. Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Medical and Pediatric Oncology 2000, 35:449-455.
6. Parasole R., Petruzziello F., Menna G., et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leukemia and Lymphoma 2011, 51:1063-1071.
7. Schmidt K., Schulz A.S., Debatin K.M., Friedrich W., Classen C.F. CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors. Pediatric Blood and Cancer 2008, 50:331-336.
8. Kuskonmaz B., Unal S., Gumruk F., Cetin M., Tuncer A.M., Gurgey A. The neurologic complications in pediatric acute lymphoblastic leukemia patients excluding leukemic infiltration. Leukemia Research 2006, 30:537-541.
9. Lim Y.J., Kim H.J., Lee Y.J., Seol I.J., Lee Y.H. Clinical features of encephalopathy in children with cancer requiring cranial magnetic resonance imaging. Pediatric Neurology 2011, 44:433-438.
10. Henderson G.B., Tsuji J.M. Identification of the bromosulfophthalein-sensitive efflux route for methotrexate as the site of action of vincristine in the vincristine-dependent enhancement of methotrexate uptake in L1210 cells. Cancer Research 1988, 48:5995-6001.
11. Naing A., Luong D., Extermann M. Methotrexate-induced status epilepticus. American Journal of Hematology 2005, 80:35-37.
12. Badell I., Munoz A., Estella J., et al. Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998. Clinical and Translational Oncology 2008, 10:117-124.
13. Kim H., Lee J.H., Choi S.J., et al. Risk score model for fatal intracranial hemorrhage in acute leukemia. Leukemia 2006, 20:770-776.
14. Ruggiero A., Attina G., Piastra M., et al. Severe hyperleukocytosis and multifocal intracranial haemorrhage: not always a fatal outcome. International Journal of Hematology 2009, 90:87-90.
15. Chen C.Y., Tai C.H., Tsay W., Chen P.Y., Tien H.F. Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. Annals of Oncology 2009, 20:1100-1104.
16. Gugliotta L., Mazzucconi M.G., Leone G., et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving l-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. European Journal of Haematology 1992, 49:63-66.
17. Kieslich M., Porto L., Lanfermann H., Jacobi G., Schwabe D., Bohles H. Cerebrovascular complications of l-asparaginase in the therapy of acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 2003, 25:484-487.
18. Nowak-Göttl U., Wolff J.E.A., Kuhn N. Enhanced thrombin generation, P-von Willebrand factor, P-fibrin d-dimer and P-plasminogen activator inhibitor 1: predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis 1994, 8:63-65.
19. Hongo T., Okada S., Ohzeki T., et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS Japan Association of Childhood Leukemia Study. Pediatrics International 2002, 44:293-299.
20. Narta U.K., Kanwar S.S., Azmi W. Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Critical Reviews in Oncology/Hematology 2007, 61:208-221.
21. Gallipoli P., Tang A., Leach M. Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia. British Journal of Haematology 2009, 145:270.
22. Narayanan S., Shami P.J. Treatment of acute lymphoblastic leukemia in adults. Critical Reviews in Oncology/Hematology 2012, 81:94-102.
23. Sebire G., Tabarki B., Saunders D.E., et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005, 128:477-489.
24. Monagle P., Chalmers E., Chan A., et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:887S-968S.
25. Mattioli Belmonte M., Gugliotta L., Delvos U., et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with l-asparaginase. Haematologica 1991, 76:209-214.
26. Nicholson J.C., Darmady J.M., Kohler J.A. Superior sagittal sinus thrombosis complicating maintenance treatment for acute lymphoblastic leukemia. Pediatric Hematology and Oncology 1996, 13:287-291.
27. Mahadeo K.M., Dhall G., Panigrahy A., Lastra C., Ettinger L.J. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatric Hematology and Oncology 2010, 27:46-52.
28. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leukoencephalopathy syndrome. New England Journal of Medicine 1996, 334:494-500.
29. de Laat P., Te Winkel M.L., Devos A.S., Catsman-Berrevoets C.E., Pieters R., van den Heuvel-Eibrink M.M. Posterior reversible encephalopathy syndrome in childhood cancer. Annals of Oncology 2011, 22:472-478.
30. Norman J.K., Parke J.T., Wilson D.A., McNall-Knapp R.Y. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer 2007, 49:198-203.
31. Gupta A., Swaroop C., Rastogi R., Garg R., Bakhshi S. Simultaneous occurrence of posterior reversible leukoencephalopathy syndrome in two cases of childhood acute lymphoblastic leukemia induction chemotherapy. Pediatric Hematology and Oncology 2008, 25:351-358.
32. Hualde Olascoaga J., Molins Castiella T., Souto Hernandez S., et al. Reversible posterior leukoencephalopathy: report of two cases after vincristine treatment. Anales de Pediatria (Barcelona) 2008, 68:282-285.
33. Dicuonzo F., Salvati A., Palma M., et al. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. Journal of Child Neurology 2009, 24:1013-1018.
34. Shin R.K., Stern J.W., Janss A.J., Hunter J.V., Liu G.T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology 2001, 56:388-391.
35. Morris E.B., Laningham F.H., Sandlund J.T., Khan R.B. Posterior reversible encephalopathy syndrome in children with cancer. Pediatric Blood and Cancer 2007, 48:152-159.
36. Rathi B., Azad R.K., Vasudha N., Hissaria P., Sawlani V., Gupta R.K. l-Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatric Neurosurgery 2002, 37:203-205.
37. Titos-Arcos J.C., Leon-Villar J., Amigo-Lozano M.L., Muina-Juarez B. Posterior reversible leukoencephalopathy syndrome induced by l-asparaginase in a teenage female diagnosed with acute lymphoblastic leukemia. Revista de Neurologia 2011, 52:58-60.
38. Sanchez-Carpintero R., Narbona J., Lopez de Mesa R., Arbizu J., Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatric Neurology 2001, 24:145-148.
39. Saito B., Nakamaki T., Nakashima H., et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. American Journal of Hematology 2007, 82:304-306.
40. Roth C., Ferbert A. The posterior reversible encephalopathy syndrome: what's certain, what's new?. Practical Neurology 2011, 11:136-144.
41. Cordelli D.M., Masetti R., Bernardi B., et al. Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantation. Pediatric Blood and Cancer 2012, 58(5):785-790.
42. Agarwal A., Vijay K., Thamburaj K., Ouyang T. Transient leukoencephalopathy after intrathecal methotrexate mimicking stroke. Emergency Radiology 2011, 18(4):345-347.
43. McCoy B., King M., Gill D., Twomey E. Childhood posterior reversible encephalopathy syndrome. European Journal of Paediatric Neurology 2011, 15:91-94.
44. Staykov D., Schwab S. Posterior reversible encephalopathy syndrome. Journal of Intensive Care Medicine 2012, 27(1):11-24.
45. Vagace J.M., Caceres-Marzal C., Jimenez M., Casado M.S., de Murillo S.G., Gervasini G. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. American Journal of Hematology 2011, 86:98-101.
46. Mahoney D.H., Shuster J.J., Nitschke R., et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a Pediatric Oncology Group study. Journal of Clinical Oncology 1998, 16:1712-1722.
47. Fisher M.J., Khademian Z.P., Simon E.M., Zimmerman R.A., Bilaniuk L.T., Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. American Journal of Neuroradiology 2005, 26:1686-1689.
48. Rubnitz J.E., Relling M.V., Harrison P.L., et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998, 12:1176-1181.
49. Sandoval C., Kutscher M., Jayabose S., Tenner M. Neurotoxicity of intrathecal methotrexate: MR imaging findings. American Journal of Neuroradiology 2003, 24:1887-1890.
50. Lee A.C., Li C.H., Wong Y.C. Transient encephalopathy following high-dose methotrexate. Medical and Pediatric Oncology 2003, 41:101.
51. Balin J., Parmar H., Kujawski L. Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity. Journal of the Neurological Sciences 2008, 269:169-171.
52. Eichler A.F., Batchelor T.T., Henson J.W. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-Oncology 2007, 9:373-377.
53. Kubo M., Azuma E., Arai S., Komada Y., Ito M., Sakurai M. Transient encephalopathy following a single exposure of high-dose methotrexate in a child with acute lymphoblastic leukemia. Pediatric Hematology and Oncology 1992, 9:157-165.
54. Inaba H., Khan R.B., Laningham F.H., Crews K.R., Pui C.H., Daw N.C. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Annals of Oncology 2008, 19:178-184.
55. Szawarski P., Chapman C.S. A woman who couldn't speak: report of methotrexate neurotoxicity. Postgraduate Medical Journal 2005, 81:194-195.
56. Kuker W., Bader P., Herrlinger U., Heckl S., Nagele T. Transient encephalopathy after intrathecal methotrexate chemotherapy: diffusion-weighted MRI. Journal of Neuro-Oncology 2005, 73:47-49.
57. Haykin M.E., Gorman M., van Hoff J., Fulbright R.K., Baehring J.M. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. Journal of Neuro-Oncology 2006, 76:153-157.
58. Brugnoletti F., Morris E.B., Laningham F.H., et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: serial clinical and radiologic findings. Pediatric Blood and Cancer 2009, 52:293-295.
59. Rollins N., Winick N., Bash R., Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. American Journal of Neuroradiology 2004, 25:1688-1695.
60. Shuper A., Stark B., Kornreich L., Cohen I.J., Avrahami G., Yaniv I. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Israel Medical Association Journal 2002, 4:1050-1053.
61. Glass J.O., Reddick W.E., Li C.S., Laningham F.H., Helton K.J., Pui C.H. Computer-aided detection of therapy-induced leukoencephalopathy in pediatric acute lymphoblastic leukemia patients treated with intravenous high-dose methotrexate. Magnetic Resonance Imaging 2006, 24:785-791.
62. Vezmar S., Schusseler P., Becker A., Bode U., Jaehde U. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatric Blood and Cancer 2009, 52:26-32.
63. Kishi S., Griener J., Cheng C., et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. Journal of Clinical Oncology 2003, 21:3084-3091.
64. Cole P.D., Beckwith K.A., Vijayanathan V., Roychowdhury S., Smith A.K., Kamen B.A. Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatric Neurology 2009, 40:34-41.
65. Strunk T., Gottschalk S., Goepel W., Bucsky P., Schultz C. Subacute leukoencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism. Medical and Pediatric Oncology 2003, 40:48-50.
66. Cohen I.J. Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Medical Hypotheses 2007, 68:1147-1153.
67. Bernini J.C., Fort D.W., Griener J.C., Kane B.J., Chappell W.B., Kamen B.A. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995, 345:544-547.
68. Drachtman R.A., Cole P.D., Golden C.B., et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatric Hematology and Oncology 2002, 19:319-327.
69. Allen J.C., Rosen G., Mehta B.M., Horten B. Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treatment Reports 1980, 64:1261-1273.
70. Shuper A., Stark B., Kornreich L., et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. Journal of Child Neurology 2000, 15:573-580.
71. Price R.A., Birdwell D.A. The central nervous system in childhood leukemia III. Mineralizing microangiopathy and dystrophic calcification. Cancer 1978, 42:717-728.
72. Verstappen C.C., Heimans J.J., Hoekman K., Postma T.J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003, 63:1549-1563.
73. Erbetta A., Salmaggi A., Sghirlanzoni A., et al. Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. Neurological Sciences 2008, 29:131-137.
74. Baker W.J., Royer G.L., Weiss R.B. Cytarabine and neurologic toxicity. Journal of Clinical Oncology 1991, 9:679-693.
75. Resar L.M., Phillips P.C., Kastan M.B., Leventhal B.G., Bowman P.W., Civin C.I. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993, 71:117-123.
76. Herzig R.H., Hines J.D., Herzig G.P., et al. Cerebellar toxicity with high-dose cytosine arabinoside. Journal of Clinical Oncology 1987, 5:927-932.
77. Friedman J.H., Shetty N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Movement Disorders 2001, 16:575-577.
78. Kannarkat G., Lasher E.E., Schiff D. Neurologic complications of chemotherapy agents. Current Opinion in Neurology 2007, 20:719-725.
79. Smith G.A., Damon L.E., Rugo H.S., Ries C.A., Linker C.A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Journal of Clinical Oncology 1997, 15:833-839.
80. Ellison D.H., Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. New England Journal of Medicine 2007, 356:2064-2072.
81. Hoorn E.J., Zietse R. Hyponatremia revisited: translating physiology to practice. Nephron Physiology 2008, 108:46-59.
82. Bay A., Oner A.F., Etlik O., Yilmaz C., Caksen H. Myelopathy due to intrathecal chemotherapy: report of six cases. Journal of Pediatric Hematology/Oncology 2005, 27:270-272.
83. Skullerud K., Halvorsen K. Encephalomyelopathy following intrathecal methotrexate treatment in a child with acute leukemia. Cancer 1978, 42:1211-1215.
84. Sul J.K., Deangelis L.M. Neurologic complications of cancer chemotherapy. Seminars in Oncology 2006, 33:324-332.
85. van den Berg H., van der Flier M., van de Wetering M.D. Cytarabine-induced aseptic meningitis. Leukemia 2001, 15:697-699.
86. Jabbour E., O'Brien S., Kantarjian H., et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007, 109:3214-3218.
87. Ostermann K., Pels H., Kowoll A., Kuhnhenn J., Schlegel U. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. Journal of Neuro-Oncology 2011, 103:635-640.
88. Glantz M.J., LaFollette S., Jaeckle K.A., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. Journal of Clinical Oncology 1999, 17:3110-3116.
89. Gagliano R.G., Costanzi J.J. Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 1976, 37:1663-1668.
90. Dunton S.F., Nitschke R., Spruce W.E., Bodensteiner J., Krous H.F. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study. Cancer 1986, 57:1083-1088.
91. Papayannidis C., Iacobucci I., Abbenante M.C., et al. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. American Journal of Hematology 2010, 85:608.
92. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Current Drug Metabolism 2009, 10:547-566.
93. Erdilyi D.J., Kamory E., Csokay B., et al. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics Journal 2008, 8:321-327.
94. Renbarger J.L., McCammack K.C., Rouse C.E., Hall S.D. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatric Blood and Cancer 2008, 50:769-771.
95. Moore A.S., Norris R., Price G., et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. Journal of Paediatrics and Child Health 2011, 47(12):875-882.
96. Hartman A., van Schaik R.H., van der Heiden I.P., et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leukemia Research 2010, 34:154-159.
97. Plasschaert S.L., Groninger E., Boezen M., et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics 2004, 76:220-229.
98. Rocha V., Porcher R., Fernandes J.F., et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009, 23:545-556.
99. Ngamjanyaporn P., Thakkinstian A., Verasertniyom O., et al. Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatology International 2011, 31:1215-1218.
100. Takada K., Arefayene M., Desta Z., et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and Rheumatism 2004, 50:2202-2210.
101. Su H.I., Sammel M.D., Velders L., et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and Sterility 2010, 94:645-654.
102. Cho H.J., Eom H.S., Kim H.J., Kim I.S., Lee G.W., Kong S.Y. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genetics and Cytogenetics 2010, 198:40-46.
103. Ekhart C., Rodenhuis S., Smits P.H., Beijnen J.H., Huitema A.D. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenetics and Genomics 2008, 18:1009-1015.
104. Zielinska E., Zubowska M., Misiura K. Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. Journal of Pediatric Hematology/Oncology 2005, 27:582-589.
105. Hartford C.M., Duan S., Delaney S.M., et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 2009, 113:2145-2153.
106. Chen S.H., Pei D., Yang W., et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clinical Pharmacology and Therapeutics 2010, 88:191-196.
107. Chen S.H., Yang W., Fan Y., et al. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 2011, 25:66-74.
108. Bleibel W.K., Duan S., Huang R.S., et al. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Human Genetics 2009, 125:173-180.
109. Huang R.S., Duan S., Bleibel W.K., et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:9758-9763.
110. Wessels J.A., van der Kooij S.M., Le Cessie S., et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis and Rheumatism 2007, 56:1765-1775.
111. Palmer B.F. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends in Endocrinology and Metabolism 2003, 14:182-187.